Shares of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) ended Friday session in red amid volatile trading. The shares closed down -0.07 points or -0.69% at $10.12 with 2.81 million shares getting traded. Post opening the session at $10.21, the shares hit an intraday low of $9.88 and an intraday high of $10.21 and the price vacillated in this range throughout the day. The company has a market cap of $1.92 billion and the numbers of outstanding shares have been calculated to be 192.71 million shares.
Ariad Pharmaceuticals, Inc. (ARIA) on August 30, 2016 announced it has completed the rolling submission of the New Drug Application (NDA) for its investigational anaplastic lymphoma kinase (ALK) inhibitor, brigatinib, to the U.S. Food and Drug Administration (FDA). ARIAD is seeking U.S. marketing approval of brigatinib for patients with metastatic ALK-positive (ALK+) non-small cell lung cancer (NSCLC) who are resistant or intolerant to crizotinib. The Company is seeking accelerated approval for brigatinib from the FDA and has requested a priority review of the application, which, if granted, would allow for approval of brigatinib eight months after the NDA submission, as opposed to 12 months for a standard review.
“Many patients with ALK-positive non-small cell lung cancer eventually develop disease progression,” said Corey Langer, M.D., director of thoracic oncology in the Abramson Cancer Center of the University of Pennsylvania and a professor of Hematology-Oncology in Penn’s Perelman School of Medicine. “We are excited that the brigatinib NDA submission is now complete and are hopeful that brigatinib’s data, including the observation of complete responses and activity in the central nervous system, will provide patients and their oncologists with a new treatment option.”
Shares of Hologic, Inc. (NASDAQ:HOLX) ended Friday session in green amid volatile trading. The shares closed up +0.05 points or 0.13% at $38.51 with 1.30 million shares getting traded. Post opening the session at $38.66, the shares hit an intraday low of $38.37 and an intraday high of $38.77 and the price vacillated in this range throughout the day. The company has a market cap of $10.69 billion and the numbers of outstanding shares have been calculated to be 277.42 million shares.
On Aug. 24, 2016 Hologic, Inc. (HOLX) applauds Cigna’s decision to cover breast tomosynthesis for routine breast cancer screening. Effective immediately, this new policy provides Cigna subscribers insurance coverage for Hologic’s Genius™ 3D MAMMOGRAPHY™ exam, the only mammogram clinically proven to detect cancer 15 months earlier than traditional 2D screenings.
Cigna is the first national insurer to provide coverage of 3D™ mammograms for annual breast cancer screening for all women over age 40, and for high-risk women starting at age 25. Cigna changed its policy based on recent guidance from the National Comprehensive Cancer Network (NCCN), which highlighted extensive clinical research supporting the benefits of breast tomosynthesis. With this policy change, the Genius™ 3D MAMMOGRAPHY™ exam, shown to detect 40 percent more invasive cancers and reduce recalls by up to 41 percent, is now covered for the majority of women across the United States.
“We commend Cigna for its decision to cover 3D™ mammograms for breast cancer screening and are thrilled for the millions of women who now have access to this proven technology without co-pays or out-of-pocket expenses,” said Pete Valenti, Hologic’s Division President, Breast and Skeletal Health Solutions. “We urge other national insurers to follow Cigna’s lead, because every woman in America deserves access to the Genius™ 3D MAMMOGRAPHY™ exam, which detects more invasive cancers, earlier, and helps give women the best possible chance at survival.”